LimWA, JuneCH. The principles of engineering immune cells to treat cancer. Cell, 2017; 168:724–740.
2.
SadelainM, RiviereI, RiddellS. Therapeutic T cell engineering. Nature, 2017; 545:423–431.
3.
RosenbergSA, YangJC, SherryRM, et al.Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res, 2011; 17:4550–4557.
4.
RapoportAP, StadtmauerEA, Binder-SchollGK, et al.NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med, 2015; 21:914–921.
5.
RobbinsPF, KassimSH, TranTL, et al.A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res, 2015; 21:1019–1027.
6.
GrossG, GorochovG, WaksT, et al.Generation of effector T-cells expressing chimeric T-cell receptor with antibody type-specificity. Transplant Proc, 1989; 21:127–130.
7.
KochenderferJN, WilsonWH, JanikJE, et al.Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood, 2010; 116:4099–4102.
8.
KalosM, LevineBL, PorterDL, et al.T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med, 2011; 3:95ra73.
9.
DavilaML, et al., Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014; 6:224ra25.
10.
MaudeSL, FreyN, ShawPA, et al.Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl J Med, 2014; 371:1507–1517.
11.
LeeDW, KochenderferJN, Stetler-StevensonM, et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a Phase 1 dose-escalation trial. Lancet, 2015; 385:517–528.
12.
TurtleCJ, HanafiLA, BergerC, et al.CD19 CAR-T cells of defined CD4(+): CD8(+) composition in adult B cell ALL patients. J Clin Invest, 2016; 126:2123–2138.
13.
QasimW, ZhanH, SamarasingheS, et al.Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med, 2017; 9.
14.
ParkJH, RivièreI, GonenM, et al.Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New Engl J Med, 2018; 378:449–459.
15.
MaudeSL, LaetschT, BuechnerJ, et al.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New Engl J Med, 2018; 378:439–448.
16.
KochenderferJN, et al.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol, 2015; 33:540–549.
17.
KochenderferJN, DudleyME, CarpenterRO, et al.Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood, 2013; 122:151.
18.
TurtleCJ, HanafiLA, BergerCet al.Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8(+) and CD4(+) CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med, 2016; 8:355ra116.
19.
NeelapuSS, LockeFL, BartlettNL, et al.Axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL): long-term follow-up of the pivotal Zuma-1 trial. Biol Blood Marrow Transplant, 2018; 24:S66–S67.
20.
NeelapuSS, et al.ZUMA-1 pivotal Phase 2 trial of axicabtagene ciloleucel (axi-cel, KTE-C19; anti-CD19 CAR T cells) in patients (pts) with refractory aggressive non-Hodgkin lymphoma (NHL). Mol Ther, 2017; 25:333.
21.
SchusterSJ, SvobodaJ, ChongEA, et al.Chimeric antigen receptor T cells in refractory B-cell lymphomas. New Engl J Med, 2017; 377:2545–2554.
22.
PeralesMA, KebriaeiP, KeanLS, et al.Building a safer and faster CAR: seatbelts, airbags, and CRISPR. Biol Blood Marrow Transplant, 2018; 24:27–31.
23.
JuneCH, O'ConnorRS, KawalekarOU, et al.CAR T cell immunotherapy for human cancer. Science, 2018; 359:1361–1365.
24.
FryTJ, ShahNN, OrentasRJ, et al.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med, 2018; 24:20–28.
25.
WangX, PopplewellLL, WagnerJR, et al.Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood, 2016; 127:2980–2990.
26.
ZhangCC, WangZ, YangZ, et al.Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther, 2017; 25:1248–1258.
27.
FengKC, GuoY-L, DaiH-R, et al.Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol, 2017; 10:4.
28.
JunghansRP, MaQ, RathoreR, et al.Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2–T cell pharmacodynamics as a determinant of clinical response. Prostate, 2016; 76:1257–1270.
29.
GargettT, et al.GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther, 2016; 24:1135–1149.
30.
YouFT, JiangL, ZhangB, et al.Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci, 2016; 59:386–397.
31.
Correction: Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res, 2015; 3:217.
MaQ, GarberHR, LuS, et al.A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy, 2016; 18:985–994.
34.
SrivastavaS, RiddellSR. Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J Immunol, 2018; 200:459–468.
35.
SinghH, MoyesJS, HulsMH, et al.Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther, 2015; 22:95–100.
36.
MehtaRS, RezvaniK. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol, 2018; 9:283.
37.
MirzaeiHR, MirzaeiH, LeeSY, et al.Prospects for chimeric antigen receptor (CAR) gamma delta T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett, 2016; 380:413–423.
CarrilloMA, ZhenA, ZackJA, et al.New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV. Transl Res, 2017; 187:83–92.
43.
AdairPR, KimYC, ZhangA-I, et al.Human Tregs made antigen specific by gene modification: the power to treat autoimmunity and antidrug antibodies with precision. Front Immunol, 2017; 8:1117.
